References
1. Docherty AR. Leveraging psychiatric and medical genetics to understand comorbid depression and obesity. Br J Psychiatry J Ment Sci 2017;211:61–62.
2. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220.
3. Rivera M, Locke AE, Corre T, et al. Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals. Br J Psychiatry 2017;211: 70–76.
4. Pfoh ER, Janmey I, Anand A,et al. The impact of systematic depression screening in primary care on depression identification and treatment in a large health care system: a cohort study. J Gen Intern Med 2020;35:3141–3147.
5. Siu AL, US Preventive Services Task Force; Bibbins-Domingo K, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA 2016;315:380–387.
6. Paulose-Ram R, Safran MA, Jonas BS, et al.Trends in psychotropic medication use among U. S. adults. Pharmacoepidemiol Drug Saf 2007;16:560–570.
7. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848–856.
8. Bhattacharjee S, Al Yami M, Kurdi S, et al. Prevalence, patterns and predictors of depression treatment among community-dwelling older adults with stroke in the United States: a cross sectional study. BMC Psychiatry 2018;18:130.
9. Uguz F, Sahingoz M, Gungor B, et al. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry 2015;37:46–48.
10. Blumenthal SR, Castro VM, Clements CC, et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry 2014;71: 889–896.
11. Zheng Y, Manson JE, Yuan C, et al. Associations of weight gain from early to middle adulthood with major health outcomes later in life. JAMA 2017;318:255–269.
12. Verhaegen AA, VanGaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. JEndocrinolInvest2017;40: 1165–1174.
13. Yu YH, Vasselli JR, Zhang Y, et al. Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. Obes Rev Off J Int Assoc Study Obes 2015;16: 234–247.
14. Karyotaki E, Efthimiou O, Miguel C, et al. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. JAMA Psychiatry 2021;78:361–371.
15. Angstman KB, Wade TW, Dejesus RS, et al. Patient’s weight 6 months after depression treatment is not affected by either clinical remission or enrolment in collaborative care management. Ment Health Fam Med 2013;10:15–21.
16. Fuller NR, Burns J, Sainsbury A, et al. Examining the association between depression and obesity during a weight management programme. Clin Obes 2017;7:354–359.
17. Ma J, Rosas LG, Lv N, et al. Effect of integrated behavioral weight loss treatment and problem-solving therapy on body mass index and depressive symptoms among patients with obesity and depression: the RAINBOW randomized clinical trial. JAMA 2019;321: 869–879.
18. US Preventive Services Task Force; Curry SJ, Krist AH, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA 2018;320:1163–1171.
19. Pfoh ER, Heinberg LJ, Rothberg MB. Factors impacting physician referral to and patient attendance at weight management programs within a large integrated health system. J Gen Intern Med 2021;36:2339–2345.
20. Callahan CM, Nienaber NA, Hendrie HC, et al. Depression of elderly outpatients: primary care physicians’ attitudes and practice patterns. J Gen Intern Med 1992;7:26–31.
21. Sweeten G. Group-based trajectory models. In: Bruinsma G, Weisburd D, eds., Encyclopedia of Criminology and Criminal Justice. New York: Springer; 2014:1991–2003.
22. Nagin DS, Jones BL, Passos VL, et al. Group-based multi-trajectory modeling. Stat Methods Med Res 2018;27:2015–2023.
23. Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab 2014;65: 205–210.
24. Tápias FS, Otani VHO, Vasques DAC, et al. Costs associated with depression and obesity among cardiovascular patients: medical expenditure panel survey analysis. BMC Health Serv Res 2021;21:433.
25. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018;361:k1951.
26. Wium-Andersen MK, Wium-Andersen IK, Prescott EIB, et al. An attempt to explain the bidirectional association between ischaemic heart disease, stroke and depression: a cohort and meta-analytic approach. Br J Psychiatry. 2020;217:434–441.
27. Morriss R, Tyrer F, Zaccardi F, et al. Safety of antidepressants in a primary care cohort of adults with obesity and depression. PLoS One 2021;16:e0245722.
28. Ely AC, Greiner KA, Born W, et al. Concordance of patient-physician obesity diagnosis and treatment beliefs in rural practice settings. J Rural Health 2006;22:364–366.
29. Greiner KA, Born W, Hall S, et al. Discussing weight with obese primary care patients: physician and patient perceptions. J Gen Intern Med 2008;23:581–587.
30. Bleich SN, Huizinga MM, Beach MC, et al. Patient use of weight-management activities: a comparison of patient and physician assessments. Patient Educ Couns 2010;79: 344–350.
31. Pickett-Blakely O, Bleich SN, Cooper LA. Patient-physician gender concordance and weight-related counseling of obese patients. Am J Prev Med 2011;40:616–619.
32. Stanners MN, Barton CA, Shakib S, et al. Depression diagnosis and treatment amongst multimorbid patients: a thematic analysis. BMC Fam Pract 2014;15:124.
34. Lewis KH, Edwards-Hampton SA, Ard JD. Disparities in treatment uptake and outcomes of patients with obesity in the USA. Curr Obes Rep 2016;5:282–290.
35. Gill H, Gill B, El-Halabi S, et al. Antidepressant medications and weight change: a narrative review. Obesity (Silver Spring) 2020;28:2064–2072.